about
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisClinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology.Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib.Rare and unusual clinicopathologic presentation of renal AL amyloidosis.T1 mapping in cardiac MRI.Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis.Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial.Myocardial T1 and T2 Mapping: Techniques and Clinical Applications.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Recent advances in the noninvasive strategies of cardiac amyloidosis.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.New concepts in the treatment and diagnosis of amyloidosis.Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: late gadolinium enhancement pattern as mortality predictor.Myocardial strain pattern in patients with cardiac amyloidosis secondary to multiple myeloma: a cardiac MRI feature tracking study.Amyloid Cardiomyopathy: Disease on the Rise.Light Chain Amyloidosis.Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.Recent advances in understanding and treating immunoglobulin light chain amyloidosisBase-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosisMyocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
P2860
Q28069975-9CD30D18-1E4B-4722-B074-FD4E7C126F11Q28073135-C5978D86-A774-425B-8486-42807C321D5BQ30377076-0B394789-4799-4344-9BA1-8133A058197AQ30383707-F667A6CF-F7AA-4D94-839C-BD2BE00669D3Q33844044-1954284A-FA31-4BAC-A3E1-DC087D86C8DFQ36042226-4045DA67-F7A1-492A-BFD6-88AE318F24C4Q36071494-1667E887-9406-4937-83D0-4A523A88E2E8Q37589574-79B17076-3D8D-4473-8C48-5E63F5253DE6Q38614967-1221D7D5-348D-46A2-A7D0-C7CB82A9969AQ38935425-200D8BFC-D436-4FDE-9AFC-31C6DADCB621Q39217713-36C0802B-3149-4350-A1B6-C00251955DAFQ47561519-D7FB5879-75EF-4E74-9335-A1C96BEBB67DQ47744664-3B7A6E10-4304-4B1F-B757-A0ADD781B36AQ48593562-3A3AD23A-ADCA-4476-8047-5F3CEC3E4A6DQ51817077-8D1C846D-7DBD-4845-AFF2-A585EECDB95DQ52659305-F0FBEC8D-5579-4E1B-B7DD-5D1F0FC34CFFQ55425790-B7DB47E3-353D-4C9B-9DDF-98BD5A121DF5Q57166910-2DCA50FB-088B-4B13-B3F1-DF5D7F5C64F4Q58602803-788A2A6E-52FE-4DC8-ADE0-A2ADAD20B2C3Q58773826-87101DF9-F8FA-4B78-98B6-48A413146102
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cardiovascular magnetic resonance for amyloidosis.
@ast
Cardiovascular magnetic resonance for amyloidosis.
@en
type
label
Cardiovascular magnetic resonance for amyloidosis.
@ast
Cardiovascular magnetic resonance for amyloidosis.
@en
prefLabel
Cardiovascular magnetic resonance for amyloidosis.
@ast
Cardiovascular magnetic resonance for amyloidosis.
@en
P2093
P2860
P1476
Cardiovascular magnetic resonance for amyloidosis.
@en
P2093
Marianna Fontana
Philip N Hawkins
Robin Chung
P2860
P2888
P304
P356
10.1007/S10741-014-9470-7
P50
P577
2015-03-01T00:00:00Z